Cambridge Healthtech Institute's Second Annual

Microbial Production

( 微生物表现 )

Optimizing the Expression and Production of Microbial Expressed Proteins

2018年1月11日 - 12日 | Hilton San Diego Bayfront | San Diego, CA


Microbial expression systems offer significant advantages over other hosts by providing faster development times, greater yields, lower production costs, particularly in E. coli which is one of the most widely used hosts for protein production. However, limitations around glycosylation and central metabolic pathways poses significant challenges.

Cambridge Healthtech Institute's Microbial Production conference covers the latest developments in microbial expression and production - from host strain development to metabolic engineering, assembly to scale-up, downstream processing to potential aggregation - with particular focus on the role of E. coli for biotherapeutics, novel products and other industrial applications.

Preliminary Agenda

Opportunities and Challenges in Microbial-Based Expression

Opportunities and Challenges in Microbial Production - Expression of Complex Proteins in E. coli

Dorothea Reilly, Ph.D., Associate Director, Early Stage Cell Culture, Genentech

Pfizer E. coli Expression Platform Part I: Development and Testing of an Integrated Cloning and Expression System

Kevin Rust, Ph.D., Principal Scientist, Bioprocess R&D, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc.

Pfizer E. coli Expression Platform Part II: Application of the Platform to Test Reliably and Rapidly Achieve Increased Protein Yields

Marie Caparon, Ph.D., Associate Research Fellow, Bioprocess R&D, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc.

Membrane Protein Expression in Pichia pastoris Using Autoinduction

Jonas Lee, Ph.D., Scientist, Amgen

E. coli Periplasmic Expression of Antibody Fab' Fragments

Mark Ellis, Principal Scientist, Protein Expression and Purification, UCB Pharma

Presentation to be Announced

Matthew P. DeLisa, Ph.D., William L. Lewis Professor of Engineering, Chemical and Biomolecular Engineering, Cornell University

Microbial Host Engineering, Strain Development and BioProcessing

High Throughput Screening for Refolding Conditions of Bacterially Produced Proteins

Kenneth Walker, Ph.D., Director of Research, Biologics, Amgen

Tackling Development Challenges of Non-MAb Biotherapeutics in Microbial Systems using HTPD

Georg Klima, Dipl. Ing., Executive Director, Process Science, Boehringer Ingelheim RCV GmbH & Co KG

Microbial Process Development in View of Industry 4.0

Peter Neubauer, Ph.D., Professor, Department of Bioprocess Technology, Institute of Biotechnology, Technische Universitat Berlin

A S. cerevisiae Process Characterization for Production of a Therapeutic Recombinant Protein Using a Multivariate Analysis

Juan Aon, Ph.D., Senior Manager, MCCD, RD Biopharm, R&D, GSK

Microbial Expression and Production of Pasylated Proteins and Peptides: Biobetters with Extended Half-Life and Enhanced Action

Uli Binde, Ph.D., CTO, XL-Protein

Wacker BiotechMicrobial Secretion by ESETEC®: A Cost-Efficient Alternative to Mammalian Cells for Non-Glycosylated Proteins

Sebastian Schuck, Ph.D., Head, Business Development, Wacker Biotech GmbH

Recoded E. coli for Incorporation of Non-Natural Amino Acids and Also for the Purpose of Genetic Isolation

Farren Isaacs, Ph.D., Assistant Professor, Molecular Cellular and Development Biology, Yale University

Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

Christian Harding, Ph.D., CSO, VaxNewMo

A Strategy for Production of Correctly Folded Disulfide-Rich Peptides in the Periplasm of E. coli

Natalie Saez, Ph.D., Research Officer, Institute for Molecular Bioscience, The University of Queensland

* 活动内容有可能不事先告知作更动及调整。